Skip to main content
AAWH
OTC Life Sciences

Q1 Revenue Declines 9%, Net Loss Widens Amid Ohio Antitrust Lawsuit and Negative Operating Cash Flow

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$0.57
Mkt Cap
$115.234M
52W Low
$0.26
52W High
$1.2
Market data snapshot near publication time

summarizeSummary

Ascend Wellness Holdings reported a 9% revenue decline and a 53% increase in net loss for Q1 2026, alongside a shift to negative operating cash flow. The company also disclosed a new antitrust lawsuit in Ohio and a temporary facility suspension due to a fire.


check_boxKey Events

  • Financial Deterioration

    Revenue decreased 9% to $116.9 million, and net loss widened 53% to $29.5 million in Q1 2026 compared to the prior year.

  • Negative Operating Cash Flow

    The company used $19.4 million in cash from operating activities in Q1 2026, a significant reversal from $5.9 million provided in Q1 2025.

  • Ohio Antitrust Lawsuit

    The Attorney General of Ohio filed a complaint on February 6, 2026, alleging anticompetitive collusion against the company and other multi-state operators.

  • Cannabis Rescheduling Update

    The DOJ ordered medical cannabis to Schedule III on April 23, 2026, with DEA hearings for broader rescheduling (including adult-use) set for June 29, 2026. The financial impact is currently uncertain.


auto_awesomeAnalysis

This quarterly report reveals significant financial challenges for Ascend Wellness Holdings, with a notable 9% drop in revenue and a 53% increase in net loss. The shift to negative operating cash flow, consuming $19.4 million in the quarter, is particularly concerning for the company's liquidity, despite management's assertion of adequate funds for the next twelve months. New risks include an antitrust lawsuit in Ohio and a temporary shutdown of a Michigan facility due to a fire. While the potential federal cannabis rescheduling could offer long-term tax benefits, its immediate financial impact remains unclear, and the overall picture points to a deteriorating financial position and increased operational headwinds.

At the time of this filing, AAWH was trading at $0.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $115.2M. The 52-week trading range was $0.26 to $1.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AAWH - Latest Insights

AAWH
May 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
AAWH
May 13, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
AAWH
May 05, 2026, 4:25 PM EDT
Filing Type: 8-K
Importance Score:
7
AAWH
Mar 20, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
7
AAWH
Mar 12, 2026, 5:21 PM EDT
Filing Type: 10-K
Importance Score:
9
AAWH
Mar 12, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 13, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 09, 2026, 8:13 AM EST
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 06, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
9